Search alternatives:
mean decrease » a decrease (Expand Search)
ms decrease » _ decrease (Expand Search), a decrease (Expand Search), use decreased (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
Showing 241 - 260 results of 12,387 for search '(( 50 ms decrease ) OR ( 5 ((((ng decrease) OR (mean decrease))) OR (nn decrease)) ))', query time: 0.33s Refine Results
  1. 241
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 242
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 243
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 244
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 245
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 246
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 247
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 248
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 249
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 250
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 251
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 252
    GC-MS chromatogram of garlic essential oil.

    GC-MS chromatogram of garlic essential oil. by Huda H. Elbehery (22492996)

    Published 2025
    Save to List
    Saved in:
  13. 253
    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences.

    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

    Published 2022
    Save to List
    Saved in:
  14. 254
    Distribution of mean seasonal rainfall in the study area.

    Distribution of mean seasonal rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 255
    Distribution of mean monthly rainfall in the study area.

    Distribution of mean monthly rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 256
    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone.

    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone. by Brenda Lyn A. Gavina (15285185)

    Published 2023
    Save to List
    Saved in:
  17. 257
    Descriptive statistics of data presented in Tables 2–5.

    Descriptive statistics of data presented in Tables 2–5. by Héctor Raúl Olivares-Sánchez (13014866)

    Published 2022
    Save to List
    Saved in:
  18. 258
    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression.

    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

    Published 2023
    Save to List
    Saved in:
  19. 259
    Fig 5 -

    Fig 5 - by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  20. 260
    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR.

    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:

Search Tools: